Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care-Placebo Clear all
Completed Phase 3 Interventional

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions
Fostamatinib, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

NCT03451422
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Efavaleukin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

High Pain Intervention in Cesarean Sections

NCT01298778
View directory record Official record
Conditions
Other Chronic Postoperative Pain
Interventions
Duramorph 150, Acetaminophen, Duramorph 300
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 6, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

NCT01597440
View directory record Official record
Conditions
Propionic Acidemia, Methylmalonic Acidemia
Interventions
N-carbamylglutamate, Standard of Care
Drug · Other
Lead sponsor
Mendel Tuchman
Other
Eligibility
1 Hour to 4 Weeks
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 6, 2026, 9:44 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

NCT00311987
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
3,5-Diiodothyropropionic acid (DITPA) therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 6, 2026, 9:44 AM EDT
Not yet recruiting Not applicable Interventional

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

NCT07501676
View directory record Official record
Conditions
Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions
TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
28 Years to 52 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

NCT03215940
View directory record Official record
Conditions
Chronic Pain, Widespread
Interventions
Delta-9-Tetrahydrocannabinol, Cannabidiol, Placebos
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 6, 2026, 9:44 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

NCT00419276
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Ambulatory continuous femoral nerve block for 100 hours
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Berkeley, California • San Diego, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auriculotherapy for Surgical Pain

NCT03860259
View directory record Official record
Conditions
Acute Pain, Surgery, Shoulder Pain
Interventions
Auriculotherapy cryopuncture device without nitrogen gas, Auriculotherapy cryopuncture device with nitrogen gas
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 6, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

NCT02954159
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tacrolimus, Vedolizumab, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 6, 2026, 9:44 AM EDT
Not yet recruiting Phase 3 Interventional

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

NCT07598825
View directory record Official record
Conditions
Autoimmune Hepatitis, AIH
Interventions
Inebilizumab, Placebo, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 74 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
6
States / cities
Little Rock, Arkansas • Northridge, California • Rialto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

NCT02545049
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
173
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 4 Interventional

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 6, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

NCT05758415
View directory record Official record
Conditions
Rotator Cuff Tendinopathy
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
La Mesa, California • Van Nuys, California • Winter Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571
View directory record Official record
Conditions
Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions
cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
11,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 6, 2026, 9:44 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
50
States / cities
Tucson, Arizona • Concord, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 6, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

NCT06186219
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Rituximab
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

NCT02929329
View directory record Official record
Conditions
Heart Failure
Interventions
Omecamtiv Mecarbil, Placebo, Standard of Care
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
8,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
310
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 6, 2026, 9:44 AM EDT
Completed Phase 3 Interventional

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

NCT00219011
View directory record Official record
Conditions
Heart Failure
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 6, 2026, 9:44 AM EDT